Does Rallies show Form 4 insider transactions for KMTS?

Yes. Rallies tracks KMTS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is KMTS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for KMTS. It does not provide personalized investment advice.

KMTS (Kestra Medical Technologies, Ltd. Common Stock) Stock Analysis - Insider Trades

Kestra Medical Technologies, Ltd. Common Stock (KMTS) is a publicly traded Healthcare sector company. As of May 21, 2026, KMTS trades at $20.76 with a market cap of $1.14B and a P/E ratio of -4.05. KMTS moved +4.70% today. Year to date, KMTS is -14.99%; over the trailing twelve months it is -16.69%. Its 52-week range spans $13.25 to $30.00. Analyst consensus is strong buy with an average price target of $27.00. Rallies surfaces KMTS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading KMTS stock inside the company?

Recent KMTS insider activity includes Webster Brian Daniel sold 8.15K, Webster Brian Daniel sold 6.84K, Webster Brian Daniel sold 15.00K, COHEN RAYMOND W bought 10.00K, and Webster Brian Daniel sold 15.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

KMTS Key Metrics

Key financial metrics for KMTS
Metric	Value
Price	$20.76
Market Cap	$1.14B
P/E Ratio	-4.05
EPS	$-5.13
Dividend Yield	0.00%
52-Week High	$30.00
52-Week Low	$13.25
Volume	0
Avg Volume	0
Revenue (TTM)	$59.81M
Net Income	$-113.81M
Gross Margin	40.48%

Recent KMTS Insider Trades

Webster Brian Daniel sold 8.15K (~$167.41K) on May 15, 2026.
Webster Brian Daniel sold 6.84K (~$146.92K) on May 15, 2026.
Webster Brian Daniel sold 15.00K (~$300.67K) on Apr 15, 2026.
COHEN RAYMOND W bought 10.00K (~$199.80K) on Mar 26, 2026.
Webster Brian Daniel sold 15.00K (~$304.12K) on Mar 17, 2026.

Latest KMTS News

Kestra Medical Earns 2026 USA TODAY Top Workplaces Award Based on Employee Feedback — Apr 9, 2026
Kestra Medical Posts 63% Revenue Growth to $24.6M, GAAP Loss Widens to $34.2M — Mar 18, 2026
Kestra Medical Injects $5M into Biobeat Partnership to Add Continuous BP Monitoring to ASSURE WCD — Jan 14, 2026

KMTS Analyst Consensus

6 analysts cover KMTS: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $27.00.

Common questions about KMTS

Who is trading KMTS stock inside the company?: Recent KMTS insider activity includes Webster Brian Daniel sold 8.15K, Webster Brian Daniel sold 6.84K, Webster Brian Daniel sold 15.00K, COHEN RAYMOND W bought 10.00K, and Webster Brian Daniel sold 15.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for KMTS?: Yes. Rallies tracks KMTS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is KMTS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for KMTS. It does not provide personalized investment advice.